Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy Retatrutide + Cagrilintide in Canada

Retatrutide + Cagrilintide in Canada

Retatrutide + Cagrilintide as lyophilised powder in 15 mg vials, HPLC tested each batch and kept in Canadian stock for laboratory research.

Size
$104.00$6.93/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
Reta + Cagri · Retatrutide Cagrilintide blend · Reta Cagri · LY3437943 + cagrilintide
Class
Two-peptide research blend (GIP, GLP-1 and glucagon receptor agonist + long-acting amylin analogue)
Form
Lyophilised powder, as 15 mg vials
Sizes
15 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
15 mg: 3 mL

What is Retatrutide + Cagrilintide?

Retatrutide + Cagrilintide is one vial carrying Retatrutide 0 mg and Cagrilintide 0 mg combined into a single lyophilised powder. The two are researched separately in the literature, and the studies cited on this page are those separate studies. Its sequence is recorded as Retatrutide (LY3437943) and cagrilintide in one vial; the mg split between them is still to be confirmed with the supplier. The work published on it is in human. All 8 of the 8 studies set out below are controlled trials in people. We keep it as lyophilised powder in 15 mg vials; it is research material and nothing more. It is not a drug and is not provided for use in a person or an animal.

What the research shows

StudyModelDose usedDurationFinding
Jastreboff AM et al.2023 · N Engl J Med · PMID 37366315Human, phase 2 randomised controlled trial in adults with obesity (n=338)1, 4, 8 or 12 mg once weekly, subcutaneous (4 and 8 mg arms started at 2 or 4 mg; 12 mg started at 2 mg), vs placebo48 weeksMean body weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg) vs −2.1% with placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate.
Bajaj HS et al.2026 · Lancet · PMID 42250575Human, phase 3 randomised controlled trial in adults with type 2 diabetes (n=537)4, 9 or 12 mg once weekly, subcutaneous, vs placebo40 weeksHbA1c fell by 1.69%, 1.86% and 1.94% with 4, 9 and 12 mg vs 0.81% with placebo, and body weight changed by −11.5%, −13.9% and −15.3% vs −2.6%. Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo.
Sanyal AJ et al.2024 · Nat Med · PMID 38858523Human, phase 2a randomised controlled substudy in adults with MASLD and ≥10% liver fat (n=98)1, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo48 weeks (liver fat primary endpoint at 24 weeks)Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg) and −82.4% (12 mg) vs +0.3% with placebo.
Urva S et al.2022 · Lancet · PMID 36354040Human, phase 1b randomised multiple-ascending dose trial in type 2 diabetes (n=72)0.5, 1.5, 3, 3/6 or 3/6/9/12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg12 weeksTreatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent.
Lau DCW et al.2021 · Lancet · PMID 34798060Human, phase 2 randomised controlled trial, cagrilintide alone, adults with overweight or obesity without diabetes (n=906 randomised: 706 cagrilintide, 99 liraglutide, 101 placebo)Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly, subcutaneous; comparator liraglutide 3.0 mg once daily26 weeks treatment (including up to 6 weeks escalation), plus 6 weeks follow-upMean weight reduction was 6.0%–10.8% across the cagrilintide doses versus 3.0% with placebo. Cagrilintide 4.5 mg reduced weight by 10.8% compared with 9.0% for liraglutide 3.0 mg.
Gabe MBN et al.2024 · Diabetes Obes Metab · PMID 39279639Human, randomised double-blind thorough QT study, cagrilintide alone, healthy participants (n=105)Cagrilintide once weekly subcutaneous, escalated to 4.5 mg; placebo arms received moxifloxacin 400 mg as a positive controlNot stated in the abstractNo clinically relevant QTcF prolongation occurred after the last 4.5 mg dose; the upper limits of the 90% confidence intervals of the placebo-adjusted changes were below 10 ms at all time points.
Frias JP et al.2023 · Lancet · PMID 37364590Human, phase 2 randomised double-blind trial, CagriSema (cagrilintide + semaglutide) vs semaglutide vs cagrilintide, type 2 diabetes on metformin (n=92)CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg once weekly subcutaneous32 weeksHbA1c fell by 2.2 points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide alone. Body weight fell by 15.6%, 5.1% and 8.1% respectively. The partner drug in this trial was semaglutide, not retatrutide.
Garvey WT et al.2025 · N Engl J Med · PMID 40544433Human, phase 3a randomised controlled trial (REDEFINE 1), CagriSema vs each component vs placebo, adults with overweight or obesity without diabetes (n=3417)Cagrilintide 2.4 mg + semaglutide 2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, once weekly68 weeksMean body weight change was −20.4% with CagriSema (cagrilintide with semaglutide) versus −3.0% with placebo. The abstract does not report the result for the cagrilintide-alone arm.

What these studies don't show: Controlled trials exist, but the questions they answer are narrow. The choice of who was enrolled, what was measured and over what period all bound the meaning of the results. None of it settles safety beyond the specific conditions of each trial. Testing confirms identity and purity; it is no evidence of an effect.

Every study links to its PubMed record. See all Retatrutide + Cagrilintide studies in the research library →

Retatrutide + Cagrilintide price in Canada: 15mg vial

Buy Retatrutide + Cagrilintide in Canada in a 15mg vial. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
15 mg$104.00$6.93/mg

Is Retatrutide + Cagrilintide available in Canada?

No product containing Retatrutide + Cagrilintide carries a Drug Identification Number in Canada. Its safety, efficacy and quality have not been reviewed by any regulator here. Borealis Peptides provides it strictly for in-vitro laboratory research, never for human or veterinary use. How Health Canada treats research peptides →

Side effects reported in studies

Every statement here is linked to the study that reported it. Any tolerability finding below is a direct quote from its source study. Human work on this scale does not pin down a safety profile.

Retatrutide + Cagrilintide FAQ

What is Retatrutide + Cagrilintide?

Retatrutide + Cagrilintide is a two-peptide research blend (GIP, GLP-1 and glucagon receptor agonist + long-acting amylin analogue), and that classification is the point from which its published record begins. Its published work is in human. Borealis Peptides provides it as lyophilised powder in 15 mg vials for in-vitro laboratory research. None of this is a medicine, and it is not for human or veterinary use. Below, each cited paper appears with the system it used and what it found.

Where can I buy Retatrutide + Cagrilintide in Canada?

Straight from Borealis Peptides, kept in Canadian stock so nothing crosses a border to reach you. Available in 15 mg vials. Purity is verified by HPLC one batch at a time, and we supply for laboratory research only. Each batch has its own HPLC analysis, keyed to the number printed on the vial.

Is Retatrutide + Cagrilintide legal in Canada?

No product containing Retatrutide + Cagrilintide carries a Drug Identification Number in Canada. Its safety, efficacy and quality have not been reviewed by any regulator here. Borealis Peptides provides it strictly for in-vitro laboratory research, never for human or veterinary use. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we read it as what the material is for, well short of any permission to use it. Establishing lawful use in your own setting is down to you.

How much Retatrutide + Cagrilintide should I use?

There is none to give. Nothing on this site amounts to a protocol, a schedule or a reconstitution volume. The amounts in the cited studies belong to those studies and the models they ran in, and they are listed so the evidence can be weighed rather than accepted on trust.

What human evidence is there for Retatrutide + Cagrilintide?

Of the 8 studies cited, 8 are controlled trials in people, with the remainder being animal or cell work. Every row states its model, the amount used and the authors' reported finding, so each study's weight can be assessed first-hand instead of through a summary.

How is Retatrutide + Cagrilintide stored?

The sealed vial is stored at −20 °C, away from light and moisture. Solutions are held at 2–8 °C. Since the dry form holds up at room temperature, shipping calls for no cold chain; put it in the fridge on arrival. Light and repeated warming cause more harm than the journey does.

How is the purity of Retatrutide + Cagrilintide confirmed?

Each batch is HPLC tested before sale, and the certificate refers to the batch in your vial rather than to the product as a whole. Filing that batch number with your records is what lets an observation be reproduced later. Certificates are available on request.

How does Retatrutide + Cagrilintide compare with Retatrutide and Cagrilintide?

They are distinct compounds with distinct published records, and this site does not rank them. Retatrutide and Cagrilintide have 6 cited studies and 8 cited studies on their page against 8 here. What sets them apart is the published work, which both pages lay out in full.

Compare with